Onchilles’ scientific founder, Dr. Lev Becker, discovered that human neutrophils release catalytically active neutrophil elastase (ELANE), which selectively and potently kills cancer cells while sparing healthy tissue including immune cells. This novel innate mechanism of action, known as the ELANE pathway, was published in the journal Cell in 2021. Targeting the ELANE pathway enables the selective eradication of cancer cells regardless of their genetic makeup, anatomical origin, or immune status. Onchilles Pharma has built an extensive translational dataset spanning 11 distinct cancer types, over 50 genetically diverse cell lines, and more than 20 animal models, further validating this approach.